November 30, 2021
J&J’s Neuroscience Renaissance? Janssen R&D Chief Readying For ‘Golden Age’
From: Endpoints News
By: Beth Snyder Bulik
Bill Martin, Janssen’s global head of neuroscience for research and development now for 18 months, is looking to build out precision products as neuroscience “enters a golden age.”
Janssen’s neuroscience push also includes moving ahead in Alzheimer’s disease. Although it’s worked in Alzheimer’s research for years, Janssen has generally flown under the radar. However, it now has not one but two Alzheimer’s candidates.
Still, with the Alzheimer’s meds likely a ways off, Janssen’s more immediate non-psychiatry priority drugs include the recently launched Ponvory to treat relapsing forms of multiple sclerosis. While it’s a later entrant in the category — it’s the fourth S1P receptor modulator after Novartis’ Gilenya and Mayzent and Bristol Myers Squibb’s Zeposia — Ponvory has picked up initial interest from neurologists. Spherix Global Insights research found that doctors were open to more options in general for MS patients, but for Ponvory specifically for certain patients like those considering having children because it clears from the body quickly… (read more)